Post di Massimiliano Mezzanzanica

𝗚𝗿𝗲𝗮𝘁 𝗻𝗲𝘄𝘀 𝗳𝗼𝗿 𝗢𝗦𝗡𝗔 𝗯𝗿𝗲𝗮𝘀𝘁 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗻 𝘁𝗵𝗲 𝗻𝗲𝗼-𝗮𝗱𝗷𝘂𝘃𝗮𝗻𝘁 𝘀𝗲𝘁𝘁𝗶𝗻𝗴! The latest study by Bernet 𝘦𝘵 𝘢𝘭. stratifies breast cancer patients into progression risk groups based on Total Tumour Load (TTL). The clinically relevant TTL cut-off values were validated for prediction of non-SLN involvement and patient’s prognosis. In breast cancer patients who had received neo-adjuvant therapy and underwent SLNB analysis using OSNA, a TTL value of >25,000 copies/μL was associated with a higher progression risk and >15,000 copies/μL was predictive of non-SLN involvement. Read the full article here 👉 https://lnkd.in/eAgjnreZ #OSNA #SLN #BreastCancer #MolecularDiagnosis

🎀 October is Breast Cancer Awareness Month - a time to come together, raise awareness, and support those affected by this disease. 🎞 In this video, we highlight the importance of early detection in the fight against breast cancer. Did you know that when breast cancer is detected early, the 5-year survival rate can be 99%? 💡It's time to take action: - Perform regular self-exams; - Schedule clinical exams with your doctor; - Follow mammogram guidelines, especially if you're over 40. Together, we can raise awareness and save lives. Watch the video to learn more. 💗 #BreastCancerAwarenessMonth #PoweringPatientCare #EarlyDetection #PinkRibbon

Nearly 30% of women diagnosed with early-stage breast cancer develop metastatic disease, which is when the cancer can come back in another part of the body months or years after the original diagnosis. Today, Metastatic Breast Cancer Awareness Day, serves as a crucial reminder of why our Menarini Stemline team remains driven to find new options for the individuals living with metastatic breast cancer. #BreastCancerAwarenessMonth

Being diagnosed with blood cancer can change your life in an instant. To increase survivorship rates, early diagnosis and treatment are more important than ever.   But how can we achieve this? By ensuring better patient access to oncohematology testing – and harmonizing testing in blood cancer care.   Let’s unite together and bring hope to people living with blood cancer. Join us to improve access to testing 👉 https://lnkd.in/eQJJ8UUY Stay tuned for updates.   #FightBloodCancer #Bloodcancer #Cancer

Capturing T-cells fighting cancer ⚡️ on video‼️ A sensor in the cancer cell illuminates upon impact, providing real-time data to help improve treatments The cancer cell contains a sensor that lights up when it is attacked by the T-cell. This remarkable video clip (credit goes to Jeroen Slaats) vividly illustrates the process that occurs following immunotherapy and depicts a Cytotoxic T-Lymphocyte (CTL) attacking a tumor cell. Cell therapy, including the anti-tumor specific cells known as CAR-T cells, has transitioned from being a futuristic concept to a current reality in cancer treatment. Credit to Jeroen Slaats and biotech.symposium

🔔 This Patient Experience Week, we highlight findings from our Global Bladder Cancer Survey which reveals gaps in bladder cancer diagnosis experience: 🔍10% saw a doctor 5+ times before referral 📈This increased e to 16% for under 55s, 18% for women, and 21% for advanced cases. Explore the Survey report 👉 https://ow.ly/EIFs50RkZR1 #PatientExperienceWeek #BladderCancerSurvey #bladdercancer

In recognition of Breast Cancer Awareness Month, we are highlighting our Doxorubicin Hydrochloride reference standard: https://okt.to/h9J87k. This crucial chemotherapy drug plays a significant role in treating not only breast cancer but many other types of cancer. Doxorubicin Hydrochloride works by inhibiting topoisomerase II, which helps slow the growth of cancer cells. Ensure the highest standards in your testing with Mikromol reference standards. #BreastCancerAwareness #Mikromol #CancerResearch #Chemotherapy #PharmaQuality

October is both: #BreastCancerAwarenessMonth and! #LiverCancerAwarenessMonth Did you know that breast cancer and liver cancer are two of the 7 cancers for which alcohol is a preventable risk factor? By drinking #LessAlcohol you can reduce your risk of cancer. #RedefineAlcohol

💡 Read our latest Guidelines Spotlight! This year the ESMO Precision Medicine Working Group updated their recommendations for the use of next-generation sequencing (NGS) in advanced cancer. Reflecting advances in the field of precision oncology, the recommendations were expanded to include advanced #BreastCancer and additional rare tumor types. They also encompass the detection of tumor-agnostic alterations in metastatic cancers where access to matched therapies is available. We offer NGS applications that cover key biomarkers highlighted in the recommendations, including SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution, which has been recognized by ESMO as a validated method for HRD detection in advanced ovarian cancer. Read our blog to learn more: https://loom.ly/OPxrPKY #NGS #Oncology #ESMO